UNSPSC 51314363: Dextromethorphan/doxylamine/guaifenesin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE508. This VA Drug Class (RE508) classifies this compound as belonging to the group ANTIHISTAMINE/ANTITUSSIVE/EXPECTORANT.

UNSPSC 51314363 Dextromethorphan/doxylamine/guaifenesin is a Commodity code with minimal recent state and local activity specifically matching its scope. The three most recent opportunities posted under this code in the source—a naloxone procurement from Seminole County, Florida; a pharmacy initiative RFI from Texas HHS; and a multi-state generic pharmaceuticals cooperative contract from Minnesota—address naloxone, direct-to-manufacturer prescriptions, and broad OTC product supply respectively, none of which align with the code's stated scope of dextromethorphan/doxylamine/guaifenesin cough and cold formulations. State and local procurement offices appear to be tagging pharmaceutical and over-the-counter health products under this code inconsistently, creating a mismatch between the code's narrow chemical designation and the actual scope of work being solicited. Issuing bodies range from county health departments (Seminole County) to state health agencies (Texas HHS Commission) and regional cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance), but the diversity of products in recent postings suggests either miscoding or use of this commodity code as a catch-all for miscellaneous pharmaceutical procurement.

Geographic activity spans Florida, Texas, Minnesota, and Oregon based on the recent opportunities, with the most structured procurement activity coming from Minnesota's cooperative purchasing vehicle. The Seminole County IFB (IFB60459723LAS), posted June 30, 2026 with response due July 26, 2023, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries. The Texas HHS RFI (HHS0017013), posted April 3, 2026, explored direct-to-manufacturer prescription contracting capabilities without formal solicitation timeline. The Minnesota MMCAP RFP (S1070000015802), posted January 20, 2026 with response due March 26, 2026, targeted generic multi-source pharmaceuticals and OTC products for distribution across state and local facilities in Minnesota and Oregon, requiring compliance with cGMP, DSCSA, and FDA requirements, and assessing proposals on price competitiveness (75 percent weight), fixed pricing, EDI capability, and administrative fee agreement. Given the code mismatch and sparse relevant activity, this code warrants close tracking rather than active pursuit until state and local procurement offices apply it more consistently.